Company profile
Progyny, Inc.
NASDAQ: PGNY · Healthcare · Medical - Healthcare Plans
#137 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
71BFH 84DQ 54GM 67SS 68
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), return on assets · ↓ growth stability, listing tenure
Methodology →Revenue TTM
$1.3B
Rev growth YoY (TTM)
+6.6%
Net income (FY)
$58.5M
Employees
846
as of 2026-09-09
Market cap
$2.1B
as of 2026-09-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.3B$1.3B2025
Net income$58.5M$58.5M2025
Operating income$85.3M$85.3M2025
Total assets$742.4M$742.4M2025
Liabilities$226.4M$226.4M2025
Equity$516.0M$516.0M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY24
FY24
FY25
FY25
FY25
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Fertility benefit services revenue64%
Pharmacy benefit services revenue36%
By geography
Not disclosed.
The read
What is Progyny, Inc.’s revenue?
Progyny, Inc. booked $1.3B in FY2025 revenue, growing 311% year over year — faster than 92% of Healthcare companies we track, at a 4.5% net margin.
Peers · Healthcare
Haemonetics Corporation79B+HealthEquity, Inc.82B+Phibro Animal Health Corporation75B+Tempus AI, Inc.59CCuraleaf Holdings, Inc.49DIndivior Pharmaceuticals Inc67BNeighbors
New York →Key facts
CEOPete Anevski
SectorHealthcare
IndustryMedical - Healthcare Plans
HeadquartersNew York City, NY
ExchangeNASDAQ: PGNY
Employees846
IPO date2019-10-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.